Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 113

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Multiple sclerosis+1

Not recruiting

Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not recruiting

Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Gadobutrol
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Not recruiting

Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of ADX-914 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bempikibart
  • Sponsor:Q32 Bio Inc.

Vitiligo

Not recruiting

Study on the Safety and Effectiveness of Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Ataxia telangiectasia

Not recruiting

Study on the Effects of EryDex (Dexamethasone Sodium Phosphate) for Children Aged 6-9 with Ataxia Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Quince Therapeutics S.p.A.

Hereditary angioedema

Not recruiting

Long-term safety study of garadacimab (CSL312) for prevention of hereditary angioedema attacks

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Garadacimab
  • Sponsor:CSL Behring LLC

Paediatric acute-onset neuropsychiatric syndrome

Not recruiting

Study Comparing Human Normal Immunoglobulin and Placebo for Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Acute graft versus host disease in intestine

Not recruiting

Study on the Safety and Effectiveness of Apraglutide for Patients with Steroid-Resistant Gastrointestinal Acute Graft Versus Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

Latent autoimmune diabetes in adults

Not recruiting

Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glutamate Decarboxylase 2, Human, Recombinant
  • Sponsor:Norwegian University Of Science And Technolology

Myasthenia gravis+1

Not recruiting

Study on Ublituximab and Drug Combination for Patients with Myasthenia Gravis or Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.